TherapeuticsMD (TXMD) PT Set at $27.00 by Cantor Fitzgerald

Share on StockTwits

TherapeuticsMD (NASDAQ:TXMD) has been given a $27.00 price objective by research analysts at Cantor Fitzgerald in a report released on Sunday. The firm currently has a “buy” rating on the stock. Cantor Fitzgerald’s price target would indicate a potential upside of 386.49% from the stock’s current price.

A number of other equities analysts have also issued reports on TXMD. BidaskClub lowered shares of TherapeuticsMD from a “hold” rating to a “sell” rating in a research report on Tuesday, July 3rd. ValuEngine lowered shares of TherapeuticsMD from a “buy” rating to a “hold” rating in a research report on Saturday, July 28th. Oppenheimer set a $12.00 target price on shares of TherapeuticsMD and gave the company a “buy” rating in a research report on Monday, July 30th. JPMorgan Chase & Co. set a $11.00 target price on shares of TherapeuticsMD and gave the company a “buy” rating in a research report on Wednesday, August 15th. Finally, Zacks Investment Research downgraded shares of TherapeuticsMD from a “hold” rating to a “sell” rating in a report on Friday, August 17th. Two research analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. TherapeuticsMD presently has an average rating of “Buy” and an average target price of $15.40.

Shares of TXMD opened at $5.55 on Friday. The stock has a market capitalization of $1.52 billion, a P/E ratio of -14.95 and a beta of 1.40. The company has a debt-to-equity ratio of 0.94, a current ratio of 7.88 and a quick ratio of 7.79. TherapeuticsMD has a 52-week low of $4.34 and a 52-week high of $7.66.

TherapeuticsMD (NASDAQ:TXMD) last announced its earnings results on Monday, July 30th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.12) by ($0.03). The company had revenue of $3.80 million during the quarter, compared to the consensus estimate of $4.23 million. TherapeuticsMD had a negative net margin of 582.86% and a negative return on equity of 80.75%. The business’s quarterly revenue was down 11.6% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.10) EPS. Equities research analysts expect that TherapeuticsMD will post -0.63 EPS for the current fiscal year.

In other TherapeuticsMD news, insider John C.K. Iv Milligan sold 250,000 shares of the company’s stock in a transaction dated Tuesday, September 11th. The shares were sold at an average price of $6.10, for a total value of $1,525,000.00. Following the completion of the sale, the insider now directly owns 1,597,419 shares of the company’s stock, valued at approximately $9,744,255.90. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Brian Bernick sold 182,800 shares of the company’s stock in a transaction dated Thursday, September 13th. The shares were sold at an average price of $6.30, for a total transaction of $1,151,640.00. Following the completion of the sale, the director now directly owns 242,000 shares of the company’s stock, valued at $1,524,600. The disclosure for this sale can be found here. Insiders sold a total of 1,542,000 shares of company stock valued at $9,621,174 over the last three months. 22.85% of the stock is owned by corporate insiders.

A number of hedge funds and other institutional investors have recently modified their holdings of the business. BlackRock Inc. lifted its stake in TherapeuticsMD by 4.4% during the second quarter. BlackRock Inc. now owns 14,533,524 shares of the company’s stock valued at $90,690,000 after buying an additional 608,470 shares in the last quarter. Voya Investment Management LLC lifted its stake in TherapeuticsMD by 7.7% during the second quarter. Voya Investment Management LLC now owns 3,419,174 shares of the company’s stock valued at $21,336,000 after buying an additional 242,995 shares in the last quarter. Northern Trust Corp lifted its stake in TherapeuticsMD by 4.0% during the second quarter. Northern Trust Corp now owns 2,086,552 shares of the company’s stock valued at $13,021,000 after buying an additional 81,062 shares in the last quarter. OppenheimerFunds Inc. lifted its stake in TherapeuticsMD by 17.4% during the second quarter. OppenheimerFunds Inc. now owns 1,932,439 shares of the company’s stock valued at $12,058,000 after buying an additional 286,123 shares in the last quarter. Finally, Public Employees Retirement Association of Colorado lifted its stake in TherapeuticsMD by 2,545.7% during the second quarter. Public Employees Retirement Association of Colorado now owns 1,071,500 shares of the company’s stock valued at $6,686,000 after buying an additional 1,031,000 shares in the last quarter. 66.14% of the stock is owned by institutional investors.

About TherapeuticsMD

TherapeuticsMD, Inc operates as a women's health care product company. Its pipeline of hormone therapy drug candidates include TX-001HR, a combination of estradiol and progesterone drug candidate under clinical trials for the treatment of moderate to severe vasomotor symptoms due to menopause; TX-002HR, a natural progesterone formulation for the treatment of secondary amenorrhea without the potentially allergenic component of peanut oil; and TX-004HR, an applicator-free vaginal estradiol softgel drug candidate for the treatment of moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy in post-menopausal women with vaginal linings that do not receive enough estrogen.

See Also: What kind of dividend yield to CEF’s pay?

Analyst Recommendations for TherapeuticsMD (NASDAQ:TXMD)

Receive News & Ratings for TherapeuticsMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply